Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SNS 01

Drug Profile

SNS 01

Alternative Names: SNS-01; SNS-01-T; SNS-101

Latest Information Update: 04 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Senesco Technologies
  • Developer Senesco Technologies; Sevion Therapeutics
  • Class Antineoplastics; Gene therapies; Small interfering RNA
  • Mechanism of Action Apoptosis stimulants; Cell adhesion molecule inhibitors; Eukaryotic initiation factor 5A modulators; NF-kappa B inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Multiple myeloma; Diffuse large B cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Diffuse large B cell lymphoma; Lung cancer; Mantle-cell lymphoma; Multiple myeloma

Most Recent Events

  • 17 Nov 2014 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in South Africa (IV)
  • 17 Nov 2014 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (IV)
  • 17 Nov 2014 Suspended - Phase-I/II for Mantle cell lymphoma (Second-line therapy or greater) in South Africa (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top